Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Lajos Pusztai, MD, PhD: Update on Triplet Regimen for High-Risk HER2-Negative Breast Cancer

Posted: Monday, May 4, 2020

Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses the I-SPY2 study, which investigated the combination of durvalumab, olaparib, and paclitaxel, and its therapeutic implications for patients with high-risk HER2-negative stage II/III breast cancer or triple-negative disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.